July 24, 2020 – The U.S. FDA has approved an expanded indication for VecticalTM (calcitriol) topical
ointment, manufactured by Galderma Laboratories, to treat mild to
July 31, 2020 – The U.S. FDA has approved an expanded indication for Evotaz® (atazanavir/cobicistat) oral
tablets, manufactured by Bristol-Myers Squibb, to include its use in
July 31, 2020 – The U.S. FDA has approved a new indication for Epidiolex® (cannabidiol) oral solution,
manufactured by GW Pharmaceuticals. The drug is now indicated to
July 31, 2020 – The U.S. FDA has approved an expanded indication for Prezcobix® (darunavir/cobicistat)
oral tablets, manufactured by Janssen Pharmaceuticals. The product is
June 18, 2020 – The U.S. FDA has approved a new indication for Crysvita® (burosumab), manufactured by
Ultragenyx and Kyowa Kirin. The drug is now indicated to treat patients who are
June 17, 2020 – The U.S. FDA has approved a new indication for Keytruda® (pembrolizumab) injection,
manufactured by Merck. The drug is now indicated to treat adult and pediatric
June 16, 2020 – The U.S. FDA has approved an expanded indication for Ilaris® (canakinumab), manufactured by Novartis. The product is now indicated to treat active
June 16, 2020 – The U.S. FDA has approved a new indication for Cosentyx® (secukinumab), manufactured
by Novartis, to treat adults who have active non-radiographic axial